188宝金博页面版

Schnell et al. Cardiovasc Diabetol (2017) 16:150 DOI 10.1186/s12933-017-0633-4CORRECTIONCorrection to: Updates on cardiovascular outcome trials in diabetesOliver Schnell 1* , Lars Rydén 2 , Eberhard Standl 1 , Antonio Ceriello 3,4 and on behalf of the D&CVD EASD Study Group© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.Correction to: Cardiovasc Diabetol (2017) 16:128 https://doi.org/10.1186/s12933?017?0610?yFollowing publication of the original article [1], the authors submitted a corrected version of Table  4 (see below), as the original version contained a mistake.T h e original article has been corrected.References 1. Leiter LA, et al. Ef f i cacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Dia-betes Care. 2015;38(6):1145–53. 2. Scirica BM, et al. Saxagliptin and cardiovascular out-comes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26. 3. White WB, et  al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35. 4. Zannad F, et  al. Heart failure and mortality out-comes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a mul-ticentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–76. 5. Green JB, et  al. Ef f ect of sitagliptin on cardiovas-cular outcomes in Type 2 diabetes. N Engl J Med. 2015;373(3):232–42. 6. Pfef f er MA, et al. Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57. 7. Zinman B, et al. Empaglif l ozin, cardiovascular out-comes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. 8. Marso SP, et  al. Liraglutide and cardiovascu-lar outcomes in Type 2 diabetes. N Engl J Med. 2016;375(4):311–22 9. Marso SP, et  al. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. 10. Holman RR, et al. Ef f ects of once-weekly exenatide on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2017;377(13):1228–39. 11. Marso SP, et  al. Ef f i cacy and safety of degludec versus glargine in Type 2 diabetes. N Engl J Med. 2017;377(8):723–32. 12. Neal B, et  al. Canaglif l ozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377(7):644-57. 13. Holman RR, et  al. Ef f ects of acarbose on cardio-vascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tol-erance (ACE): a randomised, double-blind, pla-cebo-controlled trial. Lancet Diabetes Endocrinol. 2017;S2213-8587(17):30309–1.Open AccessCardiovascular Diabetology*Correspondence: oliver.schnell@lrz.uni?muenchen.de 1 Forschergruppe Diabetes e. V., Ingolstaedter Landstraße 1, Neuherberg, 85764 Munich, GermanyFull list of author information is available at the end of the article